The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD. Related Content:

• Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments
• Pridopidine in Amyotrophic Lateral Sclerosis
• Platform Trials in ALS
• Verdiperstat in Amyotrophic Lateral Sclerosis
• Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
• CNM-Au8 in Amyotrophic Lateral Sclerosis

Understanding health conditions with the most spending and variation across locations and over time is important for identifying trends, inequalities, and strategies for lowering health spending. Joseph Dieleman, PhD, of the University of Washington speaks with JAMA Associate Editor Karen Joynt Maddox, MD, MPH, about county-level variation in health care spending across the US. Related Content:

• Tracking US Health Care Spending by Health Condition and County

Two recent studies published in JAMA provide evidence about the effects of state-level abortion restrictions on birth rates and infant mortality. Author Alyssa Bilinski, PhD, MSc, of Brown University School of Public Health joins JAMA Deputy Editor Tracy Lieu, MD, to discuss her related Editorial "Abortion May Be Controversial—Supporting Children and Families Need Not Be." Related Content:

• Abortion May Be Controversial—Supporting Children and Families Need Not Be

Contemporary models of dementia care are multidisciplinary and aim to bridge medical and social services. Julie P. W. Bynum, MD, MPH, of the University of Michigan speaks with JAMA Deputy Editor Christopher C. Muth, MD, about 2 trials—the D-CARE and IN-PEACE trials—that evaluated care models to support people diagnosed with dementia and their caregivers. Related Content:

• Challenges and Innovations in Dementia Care—Evaluating Comprehensive Models
• Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers
• Palliative Care Program for Community-Dwelling Individuals With Dementia and Caregivers

Two new trials published in JAMA evaluate the efficacy of periprocedural intra-arterial thrombolytics after successful endovascular thrombectomy for patients with acute ischemic stroke. Diederik Dippel, MD, PhD, of Erasmus University Medical Center discusses this and more with JAMA Deputy Editor Christopher C. Muth, MD. Related Content:

• Intra-Arterial Thrombolytics During Thrombectomy for Ischemic Stroke—End of the Story or a New Beginning?
• Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke
• Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke

Private equity acquisitions of health care facilities have rapidly increased over the past decade. However, little is known about the effects of these acquisitions on patient experience. Author Rishi K. Wadhera, MD, MPP, MPhil, of Harvard Medical School discusses this topic with JAMA Associate Editor Karen Joynt Maddox, MD, MPH. Related Content:

• Changes in Patient Care Experience After Private Equity Acquisition of US Hospitals

Certain CD4+ T-cell subtypes play a role in asthma. Characterizing asthma endotypes in diverse groups is important to help develop effective therapies for youth with asthma. Author Juan C. Celedon, MD, DrPH, University of Pittsburgh, Department of Pediatrics, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content:

• Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth

Most Medicare Advantage (MA) plans offer dental care coverage as a supplemental benefit. However,few beneficiaries are enrolled in an MA plan that provides comprehensive dental benefits. Lisa Simon, MD, DMD, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content:

• Availability of Dental Benefits Within Medicare Advantage Plans by Enrollment and County

Long COVID is now defined as a heterogeneous, infection-associated chronic condition present for at least 3 months after SARS-CoV-2 infection. Author Leora Horwitz, MD, MHS, of NYU Grossman School of Medicine joins JAMA Executive Editor Gregory Curfman, MD, to discuss the JAMA article "2024 Update of the RECOVER-Adult Long COVID Research Index." Related Content:

• 2024 Update of the RECOVER-Adult Long COVID Research Index
• Characterizing Long COVID in Children and Adolescents

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content:

• Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer